<DOC>
	<DOCNO>NCT00002807</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage cancer cell . It yet know whether radiation therapy effective observation sugery treat endometrial cancer . PURPOSE : This randomized phase III trial study radiation therapy see well work compare observation treat patient stage I stage II endometrial cancer undergone hysterectomy oophorectomy .</brief_summary>
	<brief_title>Radiation Therapy Observation Only Treating Patients With Endometrial Cancer Who Have Undergone Surgery</brief_title>
	<detailed_description>OBJECTIVES : - Compare overall survival patient intermediate-risk endometrial cancer treat pelvic radiotherapy v observation laparoscopically-assisted vaginal hysterectomy total abdominal hysterectomy bilateral salpingo-oophorectomy . - Compare time locoregional recurrence ( i.e. , vaginal mucosa elsewhere central pelvic area lateral pelvic wall ) patient treat regimen . - Compare duration ultimate pelvic control event-free survival patient treat regimen . - Compare toxic effect regimens patient . - Compare quality life patient treat regimen . - Compare sexual health issue patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify center , tumor grade ( 1 vs 2 v 3 ) , surgical staging ( yes v ) , sexual health assessment ( yes v ) . Patients undergo laparoscopic-assisted vaginal hysterectomy total abdominal hysterectomy bilateral salpingo-oophorectomy . After surgery , patient randomize 1 2 treatment arm . - Arm I : Patients undergo observation alone . - Arm II : Beginning within 12 week ( preferably within 6-8 week ) surgery , patient undergo radiotherapy 5 day week 5 week absence disease progression unacceptable toxicity . Protocol-defined brachytherapy allow . Quality life assess baseline ; 16-18 week surgery ( arm I ) 5 9 week initiate radiotherapy ( arm II ) ; 6 , 12 , 18 , 24 , 36 , 48 , 60 month . Patients follow every 3 month 2 year , every 4 month 1 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 400 patient accrue study .</detailed_description>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven adenocarcinoma adenosquamous cell carcinoma endometrium Intermediaterisk recurrence laparoscopicallyassisted vaginal hysterectomy ( without laparoscopic stag ) total abdominal hysterectomy bilateral salpingooophorectomy Postoperative pathologic stage IA/IB ( grade 3 ) , stage IC ( grade 13 ) , stage IIA ( grade ) Patients 50 % myometrial invasion ( grade 1 2 ) less 50 % myometrial invasion ( grade 3 ) positive peritoneal cytology also eligible Patients whose sole criterion increase risk positive peritoneal cytology eligible No pathologically involve lymph node stag procedure perform Stage I papillary serous clear cell endometrial cancer allow PATIENT CHARACTERISTICS : Age : Not specify Performance status : ECOG 03 Life expectancy : At least 3 year Hematopoietic : WBC least 2,000/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 10 g/dL Hepatic : Not specify Renal : Creatinine le 2 time upper limit normal No serious renal disease would preclude radiotherapy Cardiovascular : No serious cardiovascular disease would preclude radiotherapy Other : No history inflammatory bowel disease ulcerative colitis No malignancy within past 5 year except curatively treat basal cell squamous cell skin cancer , carcinoma situ cervix , colon cancer , thyroid cancer No psychiatric addictive disorder would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : No prior anticancer hormonal therapy No concurrent progestogens Radiotherapy : No prior pelvic irradiation No prior concurrent vaginal intracavitary radiotherapy Surgery : See Disease Characteristics Other : No prior anticancer therapy No concurrent anticancer therapy</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>stage I endometrial carcinoma</keyword>
	<keyword>stage II endometrial carcinoma</keyword>
	<keyword>endometrial adenocarcinoma</keyword>
	<keyword>endometrial adenosquamous cell carcinoma</keyword>
	<keyword>endometrial papillary carcinoma</keyword>
	<keyword>endometrial clear cell carcinoma</keyword>
</DOC>